摘要
目的比较沙利度胺和最佳支持治疗对晚期癌症患者生活质量改善和1年生存率的影响,评估沙利度胺的临床疗效。方法63例晚期癌症患者随机分为治疗组(沙利度胺组)和对照组(最佳支持治疗组)。治疗组33例,每晚睡前口服沙利度胺一日1次100mg,剂量逐渐增加至最高一日200mg。对照组30例接受最佳支持治疗。结果两组患者体重增加、症状改善及QOL评分显示,治疗组治疗1和3月分别提高39.4%、45.5%、48.5%;45.5%、57.6%、63.6%。对照组分别为20.0%、30.0%、23.3%;16.7%、13.3%、16.7%。治疗组改善优于对照组,且差别有统计学显著性(P<0.05)。两组患者1年生存率分别为36.3%和30%,治疗组略高于对照组,但差别未见统计学显著性(P>0.05)。治疗组主要不良反应为便秘、嗜睡和疲乏,发生率分别为30.3%、18.1%和12.1%,与对照组相比差异无统计学意义的显著性(P>0.05)。结论沙利度胺可改善晚期恶性肿瘤患者的生活质量,毒副反应可耐受。
Objective To compare the quality of life （QOL） and survival rate of patients with advanced cancer in treatment with thalidomide and with the best supports. Methods Sixty-three cases were divided randomly into the treatment group （thalidomide, n=33） and the control group （the best support treatment, n=30）. The patients in the treatment group were given thalidomide 100 mg qn and up to 200 mg qn, and those in the control group were given the best support treatment. All patients received three months treatment. Results The weight increase, symptom score, the increation of QOL were 39.4%, 45.5%, 48.5% at 1 month and 45.5%, 57.6%, 63.6% at 3 month in the treatment group. Those in the control group were 20.0%, 30.0%, 23.3%; 16.7%, 13.3%, 16.7% at 1 and 3 month respectively. The increation of QOL in the treatment group was better than that in the control group （P〈0.05）. There was no significance different in overall survival rate. The major adverse reactions were constipation, somnolence and fatigue in the treatment group （30.3%, 18.1%, 12.1% respectively） and there was no significant difference bettwen two groups （P〉0.05）. Conclusion Thalidomide can improve QOL of patients with advanced oncology, and adverse reactions are to be tolerable.
出处
《世界临床药物》
CAS
2009年第8期480-483,共4页
World Clinical Drug
关键词
肿瘤
药物疗法
沙利度胺
neoplasm
drug therapy
thalidomide
